- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04634877
Исследование пембролизумаба (MK-3475) в комбинации с адъювантной химиотерапией с лучевой терапией или без нее у участников с недавно диагностированным раком эндометрия после операции с лечебной целью (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Фаза 3, рандомизированное, двойное слепое исследование пембролизумаба по сравнению с плацебо в комбинации с адъювантной химиотерапией с лучевой терапией или без нее для лечения недавно диагностированного рака эндометрия высокого риска после операции с лечебной целью (KEYNOTE-B21 / ENGOT-en11 / GOG- 3053)
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
Обзор исследования
Статус
Условия
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Styria
-
Graz, Styria, Австрия, 8036
- Medizinische Universitat Graz ( Site 2004)
-
-
Tyrol
-
Innsbruck, Tyrol, Австрия, 6020
- Medizinische Universitaet Innsbruck ( Site 2001)
-
-
-
-
-
Buenos Aires, Аргентина, C1012AAR
- IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 1010)
-
Buenos Aires, Аргентина, C1118AAT
- Hospital Aleman ( Site 1001)
-
La Rioja, Аргентина, F5300COE
- Centro Oncologico Riojano Integral ( Site 1007)
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Аргентина, B1884BBF
- Centro de Oncología e Investigación de Buenos Aires ( Site 1005)
-
CABA, Buenos Aires, Аргентина, C1012AAR
- IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)
-
CABA, Buenos Aires, Аргентина, C1431FWO
- CEMIC ( Site 1009)
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Аргентина, C1280AEB
- Hospital Britanico de Buenos Aires ( Site 1002)
-
Mar del Plata, Buenos Aires, Аргентина, B7600FZO
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Аргентина, S2000KZE
- Instituto de Oncologia de Rosario ( Site 1004)
-
-
-
-
-
Liège, Бельгия, 4000
- CHC - Groupe Sante ( Site 2041)
-
Liège, Бельгия, 4000
- CHU Liege Sart-Tilman ( Site 2044)
-
-
Bruxelles-Capitale, Region de
-
Brussels, Bruxelles-Capitale, Region de, Бельгия, 1200
- Saint-Luc UCL ( Site 2042)
-
-
Hainaut
-
Mons, Hainaut, Бельгия, 7000
- C.I.U. Hopital Ambroise Pare ( Site 2039)
-
-
Liege
-
Verviers, Liege, Бельгия, 4800
- CHR Verviers ( Site 2035)
-
-
Oost-Vlaanderen
-
Aalst, Oost-Vlaanderen, Бельгия, 9300
- AZORG Campus Aalst-Moorselbaan ( Site 2038)
-
Ghent, Oost-Vlaanderen, Бельгия, 9000
- AZ Maria Middelares Gent ( Site 2032)
-
Ghent, Oost-Vlaanderen, Бельгия, 9000
- Universitair Ziekenhuis Gent ( Site 2037)
-
Sint-Niklaas, Oost-Vlaanderen, Бельгия, 9100
- AZ Nikolaas ( Site 2031)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Бельгия, 3000
- UZ Leuven ( Site 2040)
-
-
West-Vlaanderen
-
Kortrijk, West-Vlaanderen, Бельгия, 8500
- AZ Groeninge ( Site 2036)
-
-
-
-
Baden-Wurttemberg
-
Heilbronn, Baden-Wurttemberg, Германия, 74078
- SLK-Kliniken Heilbronn GmbH ( Site 2116)
-
Ludwigsburg, Baden-Wurttemberg, Германия, 71640
- Klinikum Ludwigsburg ( Site 2111)
-
Tübingen, Baden-Wurttemberg, Германия, 72076
- Universitaetsklinikum Tuebingen ( Site 2113)
-
-
Lower Saxony
-
Hanover, Lower Saxony, Германия, 30625
- Medizinische Hochschule Hannover-Department of Obstetrics and Gynecology ( Site 2109)
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Германия, 53127
- Universitätsklinikum Bonn-Gynaecological oncology ( Site 2103)
-
Essen, North Rhine-Westphalia, Германия, 45136
- Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 2105)
-
-
Saxony
-
Dresden, Saxony, Германия, 01307
- Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur ( Site 2104)
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Германия, 23538
- Universitätsklinikum Schleswig-Holstein ( Site 2101)
-
-
-
-
-
Thessaloniki, Греция, 546 45
- Euromedica General Clinic of Thessaloniki ( Site 2422)
-
-
Achaia
-
Pátrai, Achaia, Греция, 263 35
- General Hospital of Patras. St Andrews ( Site 2421)
-
-
Attica
-
Athens, Attica, Греция, 115 28
- Geniko Panepistimako Nosokomeio ARETEIO ( Site 2423)
-
Athens, Attica, Греция, 115 28
- Perifereiako Geniko Nosokomeio ALEXANDRA ( Site 2425)
-
Chaïdári, Attica, Греция, 124 62
- Athens University Hospital ATTIKON ( Site 2424)
-
Marousi, Attica, Греция, 151 23
- Hospital Hygeia ( Site 2426)
-
-
-
-
Capital Region
-
Copehagen, Capital Region, Дания, 2100
- Rigshospitalet University Hospital ( Site 2515)
-
Herlev, Capital Region, Дания, 2730
- Herlev Hospital ( Site 2514)
-
-
North Denmark
-
Aalborg, North Denmark, Дания, 9100
- Aalborg Universitetshospital ( Site 2511)
-
-
Region Sjælland
-
Roskilde, Region Sjælland, Дания, 4000
- Roskilde Sygehus ( Site 2513)
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Дания, 5000
- Odense Universitetshospital ( Site 2512)
-
-
-
-
-
Haifa, Израиль, 3525408
- Rambam Medical Center ( Site 2307)
-
Holon, Израиль, 5810001
- Edith Wolfson Medical Center ( Site 2306)
-
Jerusalem, Израиль, 9112001
- Hadassah Medical Center. Ein Kerem ( Site 2303)
-
Petah Tikva, Израиль, 4941492
- Rabin Medical Center ( Site 2305)
-
Ramat Gan, Израиль, 5265601
- Chaim Sheba Medical Center ( Site 2301)
-
-
-
-
-
Barcelona, Испания, 08035
- Hospital Vall D Hebron ( Site 2182)
-
Barcelona, Испания, 08036
- Hospital Clinic i Provincial ( Site 2185)
-
Córdoba, Испания, 14004
- Hospital Universitario Reina Sofia ( Site 2183)
-
Madrid, Испания, 28040
- Hospital Clinico San Carlos ( Site 2187)
-
Madrid, Испания, 28046
- Hospital Universitario La Paz ( Site 2186)
-
-
Gerona
-
Girona, Gerona, Испания, 17007
- Institut Català d'Oncologia (ICO) - Girona ( Site 2184)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Испания, 28027
- Clinica Universitaria de Navarra ( Site 2181)
-
-
-
-
-
Brescia, Италия, 25123
- Azienda Ospedaliera Spedali Civili di Brescia ( Site 2135)
-
Milan, Италия, 20132
- IRCCS Ospedale San Raffaele ( Site 2130)
-
Milan, Италия, 20141
- Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 2132)
-
Naples, Италия, 80131
- Azienda Ospedaliera Universitaria Federico II ( Site 2123)
-
Naples, Италия, 80131
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2127)
-
Padova, Италия, 35128
- Istituto Oncologico Veneto IRCCS-Oncologia 2 ( Site 2134)
-
-
Abruzzo
-
Roma, Abruzzo, Италия, 00144
- Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 2121)
-
-
Lazio
-
Rome, Lazio, Италия, 00168
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 2124)
-
-
Lombardy
-
Milan, Lombardy, Италия, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2122)
-
-
Piedmont
-
Candiolo, Piedmont, Италия, 10060
- INOC - Istituto Nazionale Oncologico Candiolo ( Site 2125)
-
-
-
-
Alberta
-
Calgary, Alberta, Канада, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 3007)
-
-
Ontario
-
Kingston, Ontario, Канада, K7L 2V7
- Kingston Health Sciences Centre ( Site 3003)
-
-
Quebec
-
Montreal, Quebec, Канада, H2X 0C1
- Centre Hospitalier de l Universite de Montreal - CHUM ( Site 3006)
-
Montreal, Quebec, Канада, H4A 3J1
- McGill University Health Centre ( Site 3005)
-
Québec, Quebec, Канада, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 3002)
-
-
-
-
Anhui
-
Hefei, Anhui, Китай, 230001
- Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 4034)
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100036
- Beijing Cancer Hospital ( Site 4048)
-
Beijing, Beijing Municipality, Китай, 100730
- Peking Union Medical College Hospital ( Site 4036)
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Китай, 400030
- Chongqing Cancer Hospital ( Site 4040)
-
-
Fujian
-
Xiamen, Fujian, Китай, 361003
- The First Affiliated Hospital of Xiamen University ( Site 4060)
-
-
Guangdong
-
Guangzhou, Guangdong, Китай, 510080
- The First Affiliated Hospital ( Site 4043)
-
-
Guangxi
-
Nanning, Guangxi, Китай, 530221
- Guangxi Medical University Affiliated Tumor Hospital ( Site 4049)
-
-
Heilongjiang
-
Harbin, Heilongjiang, Китай, 150081
- Harbin Medical University Cancer Hospital ( Site 4033)
-
-
Hubei
-
Wuhan, Hubei, Китай, 430079
- Hubei Cancer Hospital ( Site 4059)
-
-
Hunan
-
Changsha, Hunan, Китай, 410006
- Hunan Cancer Hospital ( Site 4050)
-
Changsha, Hunan, Китай, 410008
- Xiangya Hospital Central South University ( Site 4035)
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай, 210008
- Nanjing Drum Tower Hospital ( Site 4037)
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай, 530021
- Jiangxi Maternal and Child Health Hospital ( Site 4051)
-
-
Jilin
-
Changchun, Jilin, Китай, 130000
- The First Hospital of Jilin University ( Site 4057)
-
-
Shaanxi
-
Xi'an, Shaanxi, Китай, 710061
- The First Affiliated Hospital of Xi an Jiaotong University ( Site 4045)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200090
- Obstetrics and Gynecology Hosp. Fudan University ( Site 4041)
-
Shanghai, Shanghai Municipality, Китай, 200127
- Shanghai Renji Hospital Affiliated to Jiao Tong University ( Site 4053)
-
Shanghai, Shanghai Municipality, Китай, 201204
- Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 4001)
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610041
- Sichuan Cancer Hospital. ( Site 4039)
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Китай, 300000
- Tianjin Medical University Cancer Institute & Hospital ( Site 4054)
-
-
Yunnan
-
Kunming, Yunnan, Китай, 650107
- Yunnan Province Cancer Hospital-Gynecology Department ( Site 4055)
-
-
Zhejiang
-
Hangzhou, Zhejiang, Китай, 310003
- The First Affiliated Hospital, Zhejiang University-Gynecology ( Site 4002)
-
Hangzhou, Zhejiang, Китай, 310006
- Women s Hospital School of Medicine Zhejiang University ( Site 4032)
-
Wenzhou, Zhejiang, Китай, 325000
- The First Affiliated Hospital of Wenzhou Medical University ( Site 4056)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Колумбия, 050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 1096)
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Колумбия, 111511
- Instituto Nacional de Cancerología E.S.E ( Site 1094)
-
-
Departamento de Nariño
-
Pasto, Departamento de Nariño, Колумбия, 520002
- Instituto Cancerologico de Nariño S.A.S. ( Site 1092)
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Колумбия, 760032
- Fundación Valle del Lili ( Site 1093)
-
-
-
-
-
Mexico City, Мексика, 06700
- Hospital Angeles Roma ( Site 1123)
-
-
Baja California Sur
-
La Paz, Baja California Sur, Мексика, 23040
- Investigacion Onco Farmaceutica S de RL de CV ( Site 1127)
-
-
Chiapas
-
Tuxtla Gutiérrez, Chiapas, Мексика, 29090
- Hospital San Lucas Cardiologica del Sureste ( Site 1122)
-
-
Mexico City
-
Mexico City, Mexico City, Мексика, 04700
- Centro Oncologico Internacional. SEDNA ( Site 1121)
-
Mexico City, Mexico City, Мексика, 14080
- Instituto Nacional de Cancerologia ( Site 1124)
-
-
Nuevo León
-
Monterrey, Nuevo León, Мексика, 64460
- Filios Alta Medicina ( Site 1125)
-
Monterrey, Nuevo León, Мексика, 64710
- I Can Oncology Center SA de CV ( Site 1126)
-
-
-
-
-
Oslo, Норвегия, 0310
- Oslo Universitetssykehus Radiumhospitalet ( Site 2151)
-
-
Troms
-
Tromsø, Troms, Норвегия, 9019
- University Hospital of North Norway ( Site 2153)
-
-
Vest-Agder
-
Kristiansand, Vest-Agder, Норвегия, 4615
- Soerlandet sykehus HF Kristiansand ( Site 2152)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Польша, 61-866
- Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 2484)
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Польша, 08-110
- Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2487)
-
Warsaw, Masovian Voivodeship, Польша, 00-315
- Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 2481)
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Польша, 15-027
- Bialostockie Centrum Onkologii ( Site 2483)
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Польша, 44-102
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2482)
-
-
Warmian-Masurian Voivodeship
-
Olsztyn, Warmian-Masurian Voivodeship, Польша, 10-228
- Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2486)
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Польша, 25-734
- Swietokrzyskie Centrum Onkologii. ( Site 2485)
-
-
-
-
Arkhangelskaya oblast
-
Arkhangelsk, Arkhangelskaya oblast, Россия, 163045
- Arkhangelsk Clinical Oncological Dispensary ( Site 2637)
-
-
Baskortostan, Respublika
-
Ufa, Baskortostan, Respublika, Россия, 450054
- Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 2645)
-
-
Chelyabinsk Oblast
-
Chelyabinsk, Chelyabinsk Oblast, Россия, 454087
- Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)
-
-
Krasnoyarsk Krai
-
Krasnoyarsk, Krasnoyarsk Krai, Россия, 660133
- Krasnoyarsk Regional Clinical oncology dispensary ( Site 2643)
-
-
Mordoviya, Respublika
-
Saransk, Mordoviya, Respublika, Россия, 430032
- National Research Ogarev Mordovia State University ( Site 2648)
-
-
Moscow
-
Moscow, Moscow, Россия, 115522
- Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF Dep.of antitumor drug therapy #4 ( Site 2634)
-
Moscow, Moscow, Россия, 125284
- Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2631)
-
-
Nizhny Novgorod Oblast
-
Nizhny Novgorod, Nizhny Novgorod Oblast, Россия, 603126
- Scientific Research Institute of Clinical Oncology "Nizhegorodsky Regional Oncology Dospensary" ( Site 2639)
-
-
Samara Oblast
-
Samara, Samara Oblast, Россия, 443031
- Samara Regional Clinical Oncology Center-Chemotherapy Dapartment ( Site 2649)
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Россия, 197758
- Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2636)
-
-
Tatarstan, Respublika
-
Kazan', Tatarstan, Respublika, Россия, 420029
- Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2646)
-
-
Tomsk Oblast
-
Tomsk, Tomsk Oblast, Россия, 634028
- Tomsk Scientific Research Institute of Oncology-Chemotherapy ( Site 2638)
-
-
Yaroslavl Oblast
-
Yaroslavl, Yaroslavl Oblast, Россия, 150054
- Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2641)
-
-
-
-
-
Leicester, Соединенное Королевство, LE1 5WW
- Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 2249)
-
Manchester, Соединенное Королевство, M20 4BX
- The Christie Hospital NHS Foundation Trust ( Site 2243)
-
-
Bristol, City of
-
Bristol, Bristol, City of, Соединенное Королевство, BS2 8ED
- Bristol Haematology and Oncology Centre ( Site 2244)
-
-
East Riding Of Yorkshire
-
Cottingham, East Riding Of Yorkshire, Соединенное Королевство, HU165JQ
- Castle Hill Hospital-Academic Oncology ( Site 2252)
-
-
Glasgow City
-
Glasgow, Glasgow City, Соединенное Королевство, G12 0YN
- Beatson West of Scotland Cancer Centre ( Site 2247)
-
-
London, City of
-
London, London, City of, Соединенное Королевство, NW1 2PG
- UCLH NHS Foundation Trust ( Site 2242)
-
London, London, City of, Соединенное Королевство, SW3 6JJ
- Royal Marsden NHS Foundation Trust ( Site 2248)
-
Sutton, London, City of, Соединенное Королевство, SM2 5PT
- Royal Marsden Hospital Sutton-Surrey ( Site 2241)
-
-
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35249
- University of Alabama - Birmingham ( Site 3061)
-
Mobile, Alabama, Соединенные Штаты, 36604
- University of South Alabama, Mitchell Cancer Institute ( Site 3058)
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85016
- HonorHealth Research Institute - Biltmore ( Site 3043)
-
Tucson, Arizona, Соединенные Штаты, 85711
- Arizona Oncology Associates PC- HOPE ( Site 3049)
-
-
California
-
La Jolla, California, Соединенные Штаты, 92093-0698
- UCSD Moores Cancer Center ( Site 3053)
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- University Of Colorado ( Site 3051)
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06511
- Smilow Cancer Hospital at Yale New Haven ( Site 3070)
-
-
Florida
-
Miami Beach, Florida, Соединенные Штаты, 33140
- Mount Sinai Cancer Center ( Site 3081)
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30342
- Northside Hospital ( Site 3036)
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern Memorial Hospital ( Site 3044)
-
-
Indiana
-
Fort Wayne, Indiana, Соединенные Штаты, 46845
- Parkview Cancer Institute ( Site 3067)
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)
-
-
Iowa
-
Iowa City, Iowa, Соединенные Штаты, 52242
- University of Iowa Hospital and Clinics ( Site 3046)
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40207
- Norton Cancer Institute - St. Matthews ( Site 3056)
-
-
Louisiana
-
Shreveport, Louisiana, Соединенные Штаты, 71103
- WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)
-
-
Massachusetts
-
Worcester, Massachusetts, Соединенные Штаты, 01605
- University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 3037)
-
-
New York
-
Mineola, New York, Соединенные Штаты, 11501
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)
-
New York, New York, Соединенные Штаты, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)
-
The Bronx, New York, Соединенные Штаты, 10461
- Montefiore Medical Center ( Site 3065)
-
-
North Carolina
-
Durham, North Carolina, Соединенные Штаты, 27710
- Duke Cancer Center ( Site 3072)
-
-
North Dakota
-
Fargo, North Dakota, Соединенные Штаты, 58102
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)
-
-
Ohio
-
Columbus, Ohio, Соединенные Штаты, 43210
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3066)
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97210
- Legacy Good Samaritan Medical Center ( Site 3033)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Sidney Kimmel Cancer Center - Jefferson Health ( Site 3078)
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15224
- AHN West Penn Hospital ( Site 3060)
-
Willow Grove, Pennsylvania, Соединенные Штаты, 19090
- Abington Hospital - Asplundh Cancer Center ( Site 3073)
-
-
South Dakota
-
Sioux Falls, South Dakota, Соединенные Штаты, 57104
- Sanford Gynecology Oncology ( Site 3045)
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75390
- UT Southwestern Medical Center ( Site 3063)
-
-
Virginia
-
Richmond, Virginia, Соединенные Штаты, 23298
- VCU Massey Cancer Center ( Site 3068)
-
-
-
-
-
Changhua, Тайвань, 50006
- Changhua Christian Hospital ( Site 4095)
-
Taichung, Тайвань, 407
- Taichung Veterans General Hospital ( Site 4094)
-
Taipei, Тайвань, 10449
- MacKay Memorial Hospital ( Site 4092)
-
Taipei, Тайвань, 11217
- Taipei Veterans General Hospital ( Site 4093)
-
Taoyuan, Тайвань, 33305
- Linkou Chang Gung Memorial Hospital ( Site 4091)
-
-
-
-
-
Adana, Турция (Туркие), 01250
- Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2355)
-
Adana, Турция (Туркие), 01330
- Cukurova Uni. Tip Fakultesi ( Site 2353)
-
Ankara, Турция (Туркие), 06490
- Baskent Universitesi Ankara Hastanesi ( Site 2354)
-
Ankara, Турция (Туркие), 06590
- Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 2350)
-
Istanbul, Турция (Туркие), 34214
- Medipol Universite Hastanesi ( Site 2352)
-
Izmir, Турция (Туркие), 35100
- Ege University Medical Faculty ( Site 2351)
-
Izmir, Турция (Туркие), 35575
- I.E.U. Medical Point Hastanesi ( Site 2356)
-
-
-
-
Chernihiv Oblast
-
Chernihiv, Chernihiv Oblast, Украина, 14029
- Chernihiv Medical Center of Modern Oncology ( Site 2368)
-
-
Chernivetska Oblast
-
Chernivtsi, Chernivetska Oblast, Украина, 58013
- Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 2366)
-
-
Kharkiv Oblast
-
Kharkiv, Kharkiv Oblast, Украина, 61024
- SO Grigoriev Institute for Medical Radiology and Oncology of NAMS of Ukraine ( Site 2363)
-
-
Khmelnytskyi Oblast
-
Khmelnitskyi, Khmelnytskyi Oblast, Украина, 29009
- MNE "Khmelnytskyi regional antitumor center" ( Site 2365)
-
-
Kyivska Oblast
-
Kiev, Kyivska Oblast, Украина, 08720
- LISOD - Israeli Oncological Hospital MedX-ray International Group LLC ( Site 2364)
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Украина, 79031
- Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2361)
-
-
Volyn Oblast
-
Lutsk, Volyn Oblast, Украина, 43018
- Volyn Regional Clinical Hospital Regional Medical Oncology Centre ( Site 2362)
-
-
-
-
Northern Savonia
-
Kuopio, Northern Savonia, Финляндия, 70210
- Kuopio University Hospital ( Site 2543)
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Финляндия, 33520
- Tampere University Hospital ( Site 2541)
-
-
Southwest Finland
-
Turku, Southwest Finland, Финляндия, 20520
- Turku University Hospital ( Site 2542)
-
-
-
-
Ain
-
Vandœuvre-lès-Nancy, Ain, Франция, 54519
- Institut De Cancerologie De Lorraine ( Site 2072)
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Франция, 06189
- Centre Antoine Lacassagne ( Site 2073)
-
-
Calvados
-
Caen, Calvados, Франция, 14076
- Centre Francois Baclesse ( Site 2062)
-
-
Cotes-d Armor
-
Plérin, Cotes-d Armor, Франция, 22190
- Hôpital Privé Des Côtes d'Armor ( Site 2063)
-
-
Doubs
-
Besançon, Doubs, Франция, 25000
- CHU Besancon - Hopital Jean Minjoz ( Site 2068)
-
-
Gironde
-
Bordeaux, Gironde, Франция, 33076
- Institut Bergonie ( Site 2067)
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Франция, 31059
- Institut Universitaire du Cancer Toulouse - Oncopole ( Site 2065)
-
-
Herault
-
Montpellier, Herault, Франция, 34298
- Institut Regional du Cancer de Montpellier - ICM ( Site 2069)
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Франция, 44277
- Hopital prive du Confluent ( Site 2061)
-
-
Rhone
-
Pierre-Bénite, Rhone, Франция, 69310
- Centre Hospitalier Lyon Sud ( Site 2064)
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Франция, 75014
- Hopital Cochin ( Site 2070)
-
Villejuif, Île-de-France Region, Франция, 94805
- Gustave Roussy ( Site 2071)
-
-
-
-
-
Olomouc, Чехия, 77900
- Fakultni nemocnice Olomouc ( Site 2392)
-
-
Brno-mesto
-
Brno, Brno-mesto, Чехия, 62500
- Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 2394)
-
-
Praha 10
-
Prague, Praha 10, Чехия, 100 34
- Fakultni nemocnice Kralovske Vinohrady ( Site 2393)
-
-
Praha 2
-
Prague, Praha 2, Чехия, 128 08
- Vseobecna fakultni nemocnice v Praze ( Site 2391)
-
-
-
-
Araucania
-
Temuco, Araucania, Чили, 4800827
- Centro Investigación del Cáncer James Lind ( Site 1061)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Чили, 7500921
- Fundacion Arturo Lopez Perez FALP ( Site 1062)
-
Santiago, Region M. de Santiago, Чили, 8330032
- Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063)
-
Santiago, Region M. de Santiago, Чили, 8420383
- Bradfordhill-Clinical Area ( Site 1070)
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Чили, 2520598
- Oncocentro ( Site 1065)
-
-
-
-
Stockholm County
-
Solna, Stockholm County, Швеция, 171 76
- Karolinska Universitetssjukhuset Solna ( Site 2220)
-
-
Uppsala County
-
Uppsala, Uppsala County, Швеция, 751 85
- Blod-och Tumorsjukdomar ( Site 2221)
-
-
Östergötland County
-
Linköping, Östergötland County, Швеция, 581 85
- Universitetssjukhuset i Linkoping. ( Site 2222)
-
-
-
-
-
Seoul, Южная Корея, 03722
- Severance Hospital Yonsei University Health System ( Site 4062)
-
Seoul, Южная Корея, 05505
- Asan Medical Center ( Site 4061)
-
Seoul, Южная Корея, 06351
- Samsung Medical Center ( Site 4064)
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Южная Корея, 10408
- National Cancer Center ( Site 4065)
-
Seongnam-si, Kyonggi-do, Южная Корея, 13620
- Seoul National University Bundang Hospital ( Site 4063)
-
-
-
-
-
Fukuoka, Япония, 811-1395
- National Hospital Organization Kyushu Cancer Center ( Site 4193)
-
Niigata, Япония, 951-8566
- Niigata Cancer Center Hospital ( Site 4185)
-
Osaka, Япония, 541-8567
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 4188)
-
Tokyo, Япония, 160-8582
- Keio University Hospital ( Site 4191)
-
Tokyo, Япония, 135-8550
- Cancer Institute Hospital of JFCR ( Site 4196)
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Япония, 464-8681
- Aichi Cancer Center ( Site 4190)
-
-
Chiba
-
Kashiwa, Chiba, Япония, 277-8577
- National Cancer Center Hospital East ( Site 4197)
-
-
Ehime
-
Matsuyama, Ehime, Япония, 791-0280
- National Hospital Organization Shikoku Cancer Center ( Site 4181)
-
Tōon, Ehime, Япония, 791-0295
- Ehime University Hospital ( Site 4187)
-
-
Fukuoka
-
Kurume, Fukuoka, Япония, 830-0011
- Kurume University Hospital ( Site 4186)
-
-
Gunma
-
Ōta, Gunma, Япония, 373-8550
- Gunma Prefectural Cancer Center ( Site 4183)
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 060-8648
- Hokkaido University Hospital ( Site 4194)
-
-
Hyōgo
-
Akashi, Hyōgo, Япония, 673-8558
- Hyogo Cancer Center ( Site 4195)
-
-
Iwate
-
Shiwa-gun, Iwate, Япония, 028-3695
- Iwate Medical University Hospital ( Site 4189)
-
-
Okinawa
-
Ginowan, Okinawa, Япония, 901-2725
- University of the Ryukyus Hospital ( Site 4184)
-
-
Saitama
-
Hidaka, Saitama, Япония, 350-1298
- Saitama Medical University International Medical Center ( Site 4182)
-
-
Shizuoka
-
Suntogun, Shizuoka, Япония, 411-8777
- Shizuoka Cancer Center ( Site 4192)
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Has a histologically confirmed new diagnosis of Endometrial Carcinoma or Carcinosarcoma (Mixed Mullerian Tumor) and:
- Has undergone curative intent surgery that included hysterectomy and bilateral salpingo-oophorectomy; and
- Is at high risk for recurrence following treatment with curative intent surgery, ie: Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2009 surgical stage I/II with myometrial invasion of non-endometrioid histology; FIGO 2009 surgical stage I/II with myometrial invasion of any histology with known aberrant p53 expression or p53 mutation; or FIGO (2009) surgical stage III or IVA of any histology.
-
Is disease-free with no evidence of loco-regional disease or distant metastasis post operatively and on imaging.
-
Has not received any radiation or systemic therapy, including immunotherapy, hormonal therapy, or hyperthermic intraperitoneal chemotherapy (HIPEC), in any setting including the neoadjuvant setting for endometrial cancer (EC).
-
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
-
Submission of a tumor tissue sample from current diagnosis of Endometrial Carcinoma or Carcinosarcoma for prospective determination of histology and mismatch repair (MMR) status by central vendor is required for all participants.
-
Has adequate organ function within 7 days of randomization.
Exclusion Criteria:
-
Has recurrent endometrial carcinoma or carcinosarcoma.
-
Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas are also not allowed.
-
Has FIGO (2009) Surgical Stage I/II EC of endometrioid histology without a known aberrant p53 expression or p53 mutation.
-
Is known to have a deoxyribonucleic acid (DNA) polymerase epsilon catalytic subunit A (POLE) mutation.
-
Has FIGO Stage IVB disease of any histology even if there is no evidence of disease after surgery.
-
Has residual tumor whether measurable or non-measurable after surgery.
-
Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
- Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers.
-
Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
-
Has received a live vaccine within 30 days before the first dose of study intervention.
- Note: killed vaccines are allowed.
-
Has a known intolerance to study intervention (or any of the excipients).
-
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
- Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
-
Has any contraindication to the use of carboplatin or paclitaxel.
-
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
-
Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
-
Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
-
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
-
Has an active infection requiring systemic therapy.
-
Has a known history of HIV infection.
-
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
-
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
-
Has had an allogenic tissue/solid organ transplant.
-
Has not recovered adequately from surgery and/or any complications from the surgery.
-
Is breastfeeding.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Pembrolizumab + Chemotherapy
Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation. |
IV infusion
Другие имена:
IV infusion IV infusion IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel. Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Другие имена:
≥4500 cGY given according to local practice, at the discretion of the investigator If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
Другие имена:
Given according to local practice, at the discretion of the investigator
Другие имена:
|
|
Плацебо Компаратор: Placebo + Chemotherapy
Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation. |
IV infusion IV infusion IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel. Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Другие имена:
≥4500 cGY given according to local practice, at the discretion of the investigator If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
Другие имена:
Given according to local practice, at the discretion of the investigator
Другие имена:
IV infusion |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence
Временное ограничение: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence, will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS)
Временное ограничение: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 54 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Blinded Independent Central Review (BICR) or by Histopathologic Confirmation of Suspected Disease Recurrence
Временное ограничение: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by BICR or by histopathologic confirmation of suspected disease recurrence, will be presented. |
Up to approximately 42 months
|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
Временное ограничение: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
Временное ограничение: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented. |
Up to approximately 54 months
|
|
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
Временное ограничение: Up to approximately 42 months
|
DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status, will be presented. |
Up to approximately 42 months
|
|
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
Временное ограничение: Up to approximately 54 months
|
OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status will be presented. |
Up to approximately 54 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Временное ограничение: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 54 months
|
|
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Временное ограничение: Up to approximately 52 weeks
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 52 weeks
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (QoL) Score
Временное ограничение: Baseline and up to approximately 54 months
|
The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. Participant responses to questions 29 ("How would you rate your overall health during the past week?") and 30 ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented. |
Baseline and up to approximately 54 months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Function Score
Временное ограничение: Baseline and up to approximately 54 months
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented. |
Baseline and up to approximately 54 months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Endometrial Cancer (EORTC QLQ-EN24) Score
Временное ограничение: Baseline and up to approximately 54 months
|
The EORTC-QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in EORTC QLQ-E24 score will be presented. |
Baseline and up to approximately 54 months
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC
Публикации и полезные ссылки
Общие публикации
- Van Gorp T, Cibula D, Lv W, Backes F, Ortac F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B; ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024 Nov;35(11):968-980. doi: 10.1016/j.annonc.2024.08.2242. Epub 2024 Sep 14.
- Slomovitz BM, Cibula D, Lv W, Ortac F, Hietanen S, Backes F, Kikuchi A, Lorusso D, Danska-Bidzinska A, Samouelian V, Barretina-Ginesta MP, Vulsteke C, Lai CH, Pothuri B, Zhang Y, Magallanes-Maciel M, Amit A, Guarneri V, Zagouri F, Bell M, Welz J, Eminowicz G, Hruda M, Willmott LJ, Lichfield J, Wang W, Orlowski R, Aktan G, Gladieff L, Van Gorp T. Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. J Clin Oncol. 2025 Jan 20;43(3):251-259. doi: 10.1200/JCO-24-01887. Epub 2024 Oct 16.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Заболевания матки
- Заболевания половых органов, Женский
- Генитальные Новообразования, Женщины
- Новообразования матки
- Новообразования эндометрия
- Болезнь Паркинсона 4, аутосомно -доминантное тело Льюи
- Органические химические вещества
- Терапия
- Углеводороды
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Терпена
- Неорганические химические вещества
- Хлорные соединения
- Азотные соединения
- Координационные комплексы
- Таксииды
- Циклодеканы
- Diterpenes
- Платиновые соединения
- Лучевая терапия
- Доцетаксел
- Карбоплатин
- Паклитаксел
- Цисплатин
- Пембролизумаб
- Брахитерапия
Другие идентификационные номера исследования
- 3475-B21
- KEYNOTE-B21 (Другой идентификатор: MSD)
- ENGOT-en11 (Другой идентификатор: European Network for Gynaecological Oncological Trial groups)
- GOG-3053 (Другой идентификатор: Gynecologic Oncology Group)
- jRCT2031200399 (Идентификатор реестра: jRCT)
- 2020-003424-17 (Номер EudraCT)
- 2022-501973-37-00 (Идентификатор реестра: EU CT)
- U1111-1282-6430 (Идентификатор реестра: UTN)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .